Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature

Thomas E. Delea, Jonathan Karnon, Paul E. Goss

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We read with interest the study by Lønning [1] examining the cost–utility of aromatase inhibitors as adjuvant therapy in postmenopausal women with early breast cancer. We are concerned, however, with the validity of the analysis, its results and conclusions.
Original languageEnglish
Pages (from-to)197-198
Number of pages2
JournalAnnals of Oncology
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2007
Externally publishedYes

Keywords

  • Aromatase inhibitors
  • postmenopause
  • Breast cancer

Fingerprint Dive into the research topics of 'Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature'. Together they form a unique fingerprint.

  • Cite this